12,372 trials
Acute Myeloid Leukemia
Primary: Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24)…
Dengue Fever
Primary: Geometric Mean Titers (GMTs) for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, 58 — 1633.693; 1790.986; 1342.745; 1325.192 titer
Locally Advanced or Metastatic and Unresectable HCC
Primary: Overall Survival (OS) — 22.1; 15.2 months
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With…
COVID-19
Primary: Number of Participants With Sustained Recovery — 203; 190 Participants
COVID-19
Primary: Number of Participants With an Ordinal Outcome on Day 5 — 1; 1; 4; 3 Participants
Insomnia · End Stage Renal Disease
Primary: Insomnia Severity Index (ISI) Short-term — 12.47; 11.97; 13.05 score on a scale — p=0.6761
Recurrent Bacterial Vaginosis
Primary: Number of Subjects With at Least One Episode of Bacterial Vaginosis — 8 Participants
Neovascular Age-related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 6.7; 6.6 letters
Nephrolithiasis
Primary: Number of Participants With Stone Recurrences — 60; 62; 61; 49 Participants
Acne Vulgaris
Primary: Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts — -27.7; -21.7 lesion counts
Acne Vulgaris
Primary: Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts — -30.1; -20.8 lesion counts
Encopresis · Autism Spectrum Disorder
Primary: Percentage of Continent Bowel Movements — 27.33; 16.99; 20.70; 55.50 percentage of bowel movements
Newly Diagnosed Glioblastoma
Primary: Overall Survival (OS) — 16.13; 15.08 Months
Lung Biopsy
Primary: the Rate of Pneumothorax — 42; 60; 184; 168 Participants